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Abstract
Alternate splicing of serotonin (5-hydroxytryptamine; 5-HT) 2C receptor (5-HT2CR) pre-RNA is negatively regulated by
the small nucleolar RNA, Snord115, loss of which is observed in nearly all individuals with Prader-Willi Syndrome
(PWS), a multigenic disorder characterised by hyperphagia and obesity. Given the role of the 5-HT2CR in the regulation
of ingestive behaviour we investigated the pathophysiological implications of Snord115 deficiency on 5-HT2CR
regulated appetite in a genotypically relevant PWS mouse model (PWS-IC). Specifically, we demonstrate that
loss of Snord115 expression is associated with increased levels of hypothalamic truncated 5-HT2CR pre-mRNA.
The 5-HT2CR promotes appetite suppression via engagement of the central melanocortin system. Pro-opiomelancortin
(Pomc) mRNA levels within the arcuate nucleus of the hypothalamus (ARC) were reduced in PWS-IC mice. We then
went on to assess the functional consequences of these molecular changes, demonstrating that PWS-IC mice are
unresponsive to an anorectic doses of a 5-HT2CR agonist and that this is associated with attenuated activation of POMC
neurons within the ARC. These data provide new insight into the significance of Htr2c pre-mRNA processing to the
physiological regulation of appetite and potentially the pathological manifestation of hyperphagia in PWS.
Furthermore, these findings have translational relevance for individuals with PWS who may seek to control
appetite with another 5-HT2CR agonist, the new obesity treatment lorcaserin.
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Introduction
Manipulations of the central serotonin (5-hydroxytrypta-
mine; 5-HT) system elicit profound effects on feeding
behaviour [1]. Specifically, a reduction in serotonin avail-
ability or efficacy, causes hyperphagia and resultant
weight gain, whilst augmented serotonin bioavailability
or receptor-specific agonism leads to hypophagia and
weight loss. Although the anorectic action of serotonin
occurs via activation of multiple receptor subtypes, it is
the 5-HT2C receptor (5-HT2CR) that is the most pre-
dominant [2]. Genetic ablation of the 5-HT2CR gene
(Htr2c) in mice leads to hyperphagia [3], whilst receptor-
specific agonists suppress food intake by enhancing the
onset of satiety [4]. More recent investigation has identi-
fied the central melanocortin system as the principle
mediator of 5-HT2CR regulated appetite [4–6]. The ar-
cuate nucleus of the hypothalamus (ARC) contains two
discrete populations of melanocortin neurons, those syn-
thesising the anorectic melanocortin receptor (MCR)
agonist pro-opiomelanocortin (POMC) and those syn-
thesising the orexigenic MCR antagonist/inverse agonist
agouti-related peptide (AgRP); 5-HT2CRs are expressed
on, and modulating firing of, ARC POMC neurons [7].
Furthermore, 5HT2CR expression specifically on POMC
neurons is both necessary and sufficient for the promo-
tion of satiety and the regulation of body weight [5, 8].
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5-HT2CR function is influenced by two post-
transcriptional processes, with the Htr2c pre-mRNA
being subject to alternate splicing [9] and adenosine-to-
inosine RNA-editing [10]. Both these events promote the
translation of less functional receptors due to their effects
on the amino acid sequence of the critical G-protein bind-
ing domain. Specifically, RNA-editing within exon V can
result in the combinatorial conversion of five clustered
adenosine residues into inosines, leading to a change in
codon-specificity and subsequent amino acid sequence.
Alternate splicing of exon V results in a truncated protein
lacking a functional G-protein binding domain. However,
although this truncated splice variant cannot act as a re-
ceptor it plays a critical role in overall 5-HT2CR function
by forming a heterodimer and sequestering the full-length
splice variant in the endoplasmic reticulum and reducing
cell surface expression [11]. This role for the truncated 5-
HT2CR has recently been confirmed and its functional im-
portance demonstrated by microinjection into the brain of
an oligonucleotide that promotes the production of the
full-length transcript and, in turn, produces a change in
feeding behaviour [12].
Processing of Htr2c pre-RNA is mediated, in part, by
the actions of the small nucleolar RNA (snoRNA)
Snord115 (previously h/mbii-52) [13, 14] present within
the imprinted Prader-Willi syndrome (PWS) locus [15].
Loss of expression of the genes in this locus gives rise to
PWS, a congenital neuroendocrine disorder in which hy-
perphagia and obesity are the hallmark symptoms [16].
A number of in silico and in vitro studies have demon-
strated that this C/D box containing snoRNA primarily
regulates alternate splicing [17], in particular the pro-
cessing of Htr2c pre-mRNA, promoting the inclusion of
exon Vb and reducing the amount of RNA encoding the
truncated receptor (Fig. 1) [13]. Nevertheless, although
increases in RNA-editing of the HTR2C pre-RNA has
been shown in both PWS [13] and PWS mouse model
brain samples [18], to our knowledge there has never been
a clear demonstration of changes in alternate splicing.
Given the importance of 5-HT2CR function to the
regulation of food intake, it has been suggested that loss
of SNORD115 expression may influence 5-HT2CR regu-
lated appetite and could thus contribute to hyperphagia
in PWS [13]. In this work, we examine the proportion of
full-length and truncated splice variants of Htr2c mRNA
in the PWS-IC mouse. The PWS-IC mouse is a full genetic
model for PWS in which all paternally expressed genes in
the cluster are silenced and in which we have previously
demonstrated hyperphagia and abnormal feeding behav-
iour [18, 19]. We go on to assess the pathophysiological
consequences of increased levels of truncated variant Htr2c
on hypothalamic 5-HT2CR function, establishing an im-
portant role in the modulation of serotonin regulated appe-
tite, and identify serotonin-melanocortin axis dysfunction
as a potential contributing factor to hyperphagia in the
clinically salient PWS-IC mouse.
Results
Increased truncated Htr2c splice variant in hypothalamus
of PWS-IC mice
Previous investigation of Htr2c pre-mRNA modification
in PWS-IC mice at the whole brain level demonstrated
an increase of RNA-editing in the absence of a signifi-
cant effect on the presence of the truncated Htr2c
mRNA isoform [18]. A more neuroanatomically refined
analysis now reveals that virtually undetectable Snord115
expression in the hypothalamus PWS-IC mice (Fig. 2a;
t16 = 6.3, p = 0.001) is associated with a marked increase
in levels of truncated Htr2c mRNA in the same samples
(Fig. 2a; t16 = 3.1, p = 0.008). There was no significant
difference in expression of 5-HT1BR (Htr1b) transcript
(Fig. 2a; t16 = 0.8, P = 0.41). As expected, the increased
Fig. 1 Schematic outlining the binding of Snord115 to Htr2c and how alternate splicing can lead to full-length and truncated 5HT2CRs. Binding of
Snord115 to a specific sequence in exon Va of the Htr2c pre-RNA promotes the inclusion of exon Vb and the production of the full-length 5HT2CR;
the exon/alternative exon border in the proximal splice site (GG) is underlined. Skipping of exon Vb leads to the introduction of a premature “stop”
codon and the production of a truncated 5HT2CR isoform. Loss of snord115 expression, as is expected in the majority of cases of PWS, is expected to
lead to an increase in levels of the truncated 5HT2CR isoform
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levels of truncated Htr2c mRNA in turn resulted in a sig-
nificant decrease in the ratio of full-length:truncated Htr2c
in PWS-IC hypothalamus (Fig. 2b; one-tailed t-test, t16 =
2.17, P < 0.023).
Altered hypothalamic neurochemistry in PWS-IC mice
In light of this, we undertook an assessment of hypothal-
amic neurochemistry in PWS-IC mice. Serotonin supresses
appetite, a function mediated predominantly via 5-HT2CRs
of the ARC melanocortin system [2, 4–6]. Analysis of sero-
tonin regulated appetite-related neuropeptide levels by in
situ hybridisation histology (ISHH) and autoradiograph
densitometry revealed a significant reduction in ARC Pomc
mRNA expression (Fig. 3; t6 = 3.9, p = 0.008) but no change
in that of agouti-related peptide (Agrp; t6 = 0.4, p = 0.681)
or neuropeptides Y (Npy, t4 = 0.6, p = 0.14) mRNA expres-
sion in PWS-IC ARC, as compared to WT controls. Levels
of brain-derived neurotrophic factor (Bdnf) mRNA within
the ventromedial hypothalamus also did not vary between
PWS-IC and WT mice (Fig. 3; t4 = 0.6, p = 0.58).
Blunted anorectic effect of 5-HT2CR agonist in PWS-IC mice
To directly assess the functional significance of in-
creased levels of truncated Htr2c on 5-HT2CR regulated
appetite we probed the response of PWS-IC mice to an
anorectic dose of a 5-HT2CR specific agonist, WAY-
161503 [20], in a post-fast re-feeding paradigm. Dosing
with WAY-161503 produced a 20–25% decrease in food
intake as expected (Fig. 4; repeated measures ANOVA,
main effect of DOSE, F2,48 = 20.34, p = 0.001). As ob-
served previously [19], PWS-IC mice consistently con-
sumed more food than WT controls (Fig. 4; repeated
measures ANOVA, main effect of GENOTYPE, F1,24 =
11.387, p = 0.003) and WT and PWS-IC mice responded
differently to WAY-161503 (GENOTYPE X DOSE
interaction, F2,48 = 5.68, p = 0.006). Post hoc (Tukey’s)
analysis revealed that 3 mg/kg (p = 0.030) and 10 mg/kg
(p = 0.033) WAY-161503 significantly reduced consump-
tion in WT mice compared to vehicle treatment. However,
no dose of WAY-161503 significantly reduced consump-
tion relative to vehicle in PWS-IC mice (3 mg/Kg, p = 0.50;
10 mg/Kg, p = 0.26).
5-HT2CR agonist induced hypothalamic neuronal
activation in PWS-IC mice
The appetite suppressing actions of 5-HT2CR agonists
are fundamentally associated with the activation of neu-
rons of the ARC [4, 5, 7]. As expected, 3 mg/kg WAY-
161503 significantly increased the overall number of
cFOS-immunoreactive (IR) cells within the ARC (Fig. 5;
two-way ANOVA, main effect of DOSE, F1,15 = 7.13, P =
0.020). However, there was also an interaction between
DOSE and GENOTYPE (two-way ANOVA, F1,15 = 9.76,
P = 0.009). Analysis of cell counts in WT brain, at two
separate neuroanatomical levels of the ARC (−1.46 and
−1.70 mm from bregma), as well as across the rostral-
caudal extent of the nucleus, revealed a robust and sig-
nificant increase in cFOS induction (Fig. 5a, c, e; bregma
−1.46, t5 = 5.3, p = 0.010; bregma −1.70, t6 = 2.6, p =
0.042; Av, t6 = 4.0, p = 0.007). In contrast, WAY-161503
administration failed to induce cFOS-IR at any level of
the ARC in PWS-IC mice (Fig. 5b, d, f; bregma −1.46, t6
= 0.3, p = 0.75; bregma −1.70, t6 = 0.7, p = 0.487; Av, t6 =
0.8, p = 0.87). Further investigation revealed the reduced
anorectic efficacy of WAY-161503 in PWS-IC mice to
be associated with a failure to induce appropriate
Fig. 2 Increased levels of truncated Htr2c in PWS-IC hypothalamus. Gene expression and splice variant ratio was assessed using quantitative PCR
(qPCR) in macro-dissected hypothalamus. a Expression of Snord115 was absent in PWS-IC hypothalamus. This deficiency promotes alternate splicing of
Htr2c, with levels of the truncated, non-functional, receptor isoform increased in PWS-IC mice relative to WT. The level of another regionally relevant
serotonin receptor, Htr1b was unaltered in PWS-IC mice. b The consequence of increased levels of truncated Htr2c expression in PWS-IC hypothalamus,
is a significant shift in the ratio of full-length:truncated, with a decreased proportion of functional (full-length) variants. Data presented as Mean ± SEM.
Student’s t-test, *p < 0.05, **p < 0.01, **p < 0.001 compared to WT controls
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downstream POMC signalling as administration of
3 mg/kg WAY-161503 substantially increased the num-
ber of cFOS-IR POMC neurons within the ARC of WT
(Fig. 6a, c, C’), but not PWS-IC mice (Fig. 6b, d, D’).
Discussion
The contribution of the 5-HT2CR to the central regula-
tion of energy balance, together with the established role
of Snord115 in modulating 5-HT2CR function and lack
of SNORD115 expression in nearly all cases of PWS
raises the possibility that abnormalities in 5-HT2CR-me-
diated feeding circuitries in brain may contribute to the
overeating seen in PWS subjects. Using a model for
PWS that lacks Snord115 expression, the PWS-IC
mouse, we provide evidence for this idea, showing that
the predicted increases in levels of truncated Htr2c in
brain. Moreover, these molecular and behavioural effects
are further associated with evidence of reduced function
in specific brain circuits, influenced by 5-HT2CR, that
control feeding.
Although a change in full-length:truncated HTR2C
ratio as a consequence of SNORD115 loss has been
Fig. 4 Blunted feeding effects of WAY-161503 in PWS-IC mice. 60 min
food consumption upon administration of 3 mg/kg and 10 mg/kg WAY-
161503 (s.c) in WT and PWS-IC mice. PWS-IC mice are unresponsive to
an anorectic dose of the 5-HT2CR agonist WAY-161503. Data presented
as Mean ± SEM, with statistical comparison performed by One-way
repeated measure ANOVA, *p < 0.05 compared to vehicle controls
Fig. 3 Perturbed hypothalamic neurochemistry in PWS-IC mice. In situ hybridisation analysis of ARC Pomc, Agrp, Npy and Bdnf mRNA expression
in PWS-IC mice demonstrates a significant decrease in ARC Pomc mRNA expression, but no effect on ARC Agrp, Npy and Bdnf mRNA levels. Data
presented as Mean ± SEM. Student’s t-test, *p < 0.05, **p < 0.01, **p < 0.001 compared to WT controls
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predicted for PWS [13], our previous investigation of
Htr2c pre-mRNA modification in PWS-IC mice at the
whole brain level demonstrated an increase of RNA-
editing in the absence of a significant effect on proportion
of splice variants [18]. However, more neuroanatomically
refined analysis of the hypothalamus now reveals con-
comitant increased levels of the truncated Htr2c mRNA
with loss of Snord115 expression in the PWS-IC mice.
The truncated variant of 5HT2CR can dimerize with the
full-length receptor protein, sequestering it to the endo-
plasmic reticulum [11]. An increase in the abundance of
the truncated variant, as occurs in the hypothalamus of
PWS-IC mice, would therefore alter the functionality of
the serotonin signalling via 5HT2CR.
To directly assess the contribution of reduced 5-
HT2CR signalling on appetite behaviour in this model
for PWS, PWS-IC mice were treated with an anorectic
dose of a 5-HT2CR specific agonist [20]. Our finding that
PWS-IC mice exhibited insensitivity to the anorectic
effects of WAY-161503 was correlated with suppressed
agonist-induced cFos-IR in ARC POMC neurons of
PWS-IC mice. Although we anticipate altered reactivity
to WAY-161503 throughout the brain of PWS-IC mice,
we focused on ARC neurons because of the well-
established link between 5HT2CR expression on POMC
neurons and satiety and the regulation of body weight
[5, 8]. When considered in the context of the basal feed-
ing behaviour of PWS-IC mice [19], these data suggest
that Snord115 deficiency derives less functional 5-
HT2CRs that are incapable of effectuating the anorectic
actions of serotonin (via stimulation of downstream
POMC signalling) and highlights the independent
contribution of this axis to the hyperphagic nature of
PWS-IC mice.
A role for abnormal melanorcortin signalling in PWS
was underlined by ISSH analysis that demonstrated a
significant decrease in ARC Pomc mRNA, but no differ-
ential expression of Agrp or Npy in PWS-IC mice. This
Fig. 5 Decreased WAY-161503 induced cFOS induction in the ARC of PWS-IC mice. a−d Immunohistochemical detection of cFOS immunoreactivity
(denoted by black nuclear staining) within the ARC (Bregma −1.46) following administration of (a, b) vehicle and (c, d) 3 mg/kg WAY-161503 to WT
and PWS-IC mice. e, f Quantification of cFOS induction at two distinct neuroanatomical levels of ARC (−1.46 and −1.70 mm from bregma) and across
the nucleus as a whole in (e) WT and (F) PWS-IC mice following WAY-161503 administration. PWS-IC mice exhibit attenuated ARC cFOS-IR upon
WAY-161503 administration. Data presented as Mean ± SEM, with statistical comparison performed by Student’s t-test, *p < 0.05, **p < 0.01
compared to vehicle controls. Scale bar in (A), 100 μm and relates to all images. 3 V, third ventricle
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observation is supported by data from 5-HT2CR deficient
mice [21] and 5-HT2CR-VGV knock-in mice that consti-
tutively express the fully edited isoform of 5HT2CR [22],
both of which exhibit a reduction in Pomc mRNA levels.
Together these data suggest that perturbed melanocorti-
negric signalling may be a functional target for the
PWS-IC mutation. Interestingly, elevated Pomc expres-
sion is observed in neonatal PWS-IC mice and has been
implicated in the depressed feeding and early postnatal
lethality observed of these mutants [23].
For some time there has been speculation with regards
to the importance of 5HT2CR mediated appetite in PWS
due to the loss of the snoRNA SNORD115 which nega-
tively regulates the generation of a truncated splice vari-
ant of this receptor [13]. To our knowledge this is the
first in vivo demonstration that increased levels of
truncated Htr2c in a mouse model for PWS promotes a
disruption of 5-HT2C receptor-mediated appetite. Al-
though PWS symptoms observed in very rare cases with
an intact SNORD115 locus discounts this gene as causal
of PWS per se [24, 25], our data suggest that 5HT2CR
dysfunction may also contribute to hyperphagia in the
majority of cases of PWS where SNORD115 expression
is lost. However, the PWS-IC model used here also lacks
expression of all paternally expressed genes from the
PWS imprinting cluster [26]. Consequently, we cannot
exclude the involvement the loss of Necdin expression in
causing alterations in the serotonergic system of the
PWS-IC model, as specific knockout of this gene in mice
also leads to altered serotonergic neurochemistry [27]
although not, as far as we are aware, changes in
Htr2c splicing. Nevertheless, the data presented here
thereby provide new insight into the significance of
Htr2c pre-mRNA processing to the physiological
regulation of appetite and potentially the pathological
manifestation of hyperphagia in PWS. Furthermore,
these findings have translational relevance for individ-
uals with PWS who may seek to control appetite with
another 5-HT2CR agonist, namely the new obesity
treatment lorcaserin [28].
Methods
Animals
PWS-IC animals [29] were bred by transmitting the
imprinting centre (IC) mutation paternally (i.e. PWS-
IC+/−). PWS-IC and WT littermates were housed in
Fig. 6 Decreased WAY-161503 induced activation of ARC POMC neurons in PWS-IC mice. Dual immunofluorescence histochemical colocalisation
of cFOS (nuclear, green) and POMC (cytoplasmic, red) in the brains of (a, c) vehicle and (B, D) WAY-161503 treated (a, c) WT and (b, d) PWS-IC
mice. Inserts in (c, d) represent high magnification images of colocalisation. WAY-161503 administration failed to activate ARC POMC neurons in
PWS-IC mice. VMH, ventromedial nucleus of the hypothalamus; 3 V, third ventricle. Scale bar (a), 100 μm and relates to (a–d). Scale bar (C’), 25 μm
and relates to (C’ and D’)
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single-sex groups, were subject to a 12 h light/dark
cycle, and had ad libitum access to standard chow
and water, unless stated otherwise.
Feeding studies
Daily consumption of a standard (3.68 kcal/g –fat 10%,
protein 20%, carbohydrate 70%) and high-fat diet
(4.54 kcal/g –fat 45%, protein 20%; carbohydrate 35% -
Special Diet Services, Witham, Essex, UK) was assessed
over two consecutive 7-day periods. Food consumption
was normalised to body weight0.75 (BW0.75).
Analysis of Htr2c mRNA processing
Whole hypothalamus was macro-dissected using a
protocol established in the laboratory [30] and RNA iso-
lated using standard Trizol methods and reverse-
transcribed using SuperScript® III First-Strand Synthesis
SuperMix (Invitrogen). Gene expression was assessed
using qPCR, performed with custom designed primers
and was analysed using the ΔCt method, normalising to
18 s rRNA as described previously [18]. Ratios of full-
length:truncated Htr2c were calculated using a modified
ΔCt method as follows:
Htr2c‐full−Htr2c‐trunc
All data were then transformed as usual (2-ΔCT) before
statistical analysis. WT n = 10, PWS-IC n = 8.
In situ hybridisation histochemistry (ISHH)
Adult brain tissue was collected from animals transcar-
dially perfused with 10% formalin, cryoprotected in 20%
sucrose and sectioned at 25 μm on a freezing micro-
tome. Tissue was processed for in situ hybridisation as
previously described [31]. Radiolabelled riboprobes spe-
cific to the mRNA sequences of Pomc, Agrp, Npy and
Bdnf were used to detect gene expression [7, 32, 33].
Riboprobes were synthesized by PCR using cDNA ob-
tained from normal mouse brain. Recombinant plasmids
were linearised by restriction digest and subjected to in
vitro transcription with a T7 RNA polymerase in the
presence of 35S-labeled UTP, according to the manufac-
turer’s instructions (Ambion Inc, Austin, Tx). Ribo-
probes were diluted to 2x107 cpm/ml in hybridization
solution. Before hybridization, brain sections were fixed
in 4% formaldehyde in DEPC-treated PBS and permeabi-
lised by heating in prewarmed sodium citrate buffer
(95–100 °C, pH 6.0), before being dehydrated in ascend-
ing concentrations of ethanol, and air-dried. Probe
solution was applied to each slide and sections were in-
cubated for 12–16 h at 57 °C. After this time slides were,
incubated in 0.002% RNase A (Qiagen, Valencia, CA),
followed by sequential washes in decreasing concentra-
tions of sodium citrate buffer (SSC). The sections were
dehydrated in ascending concentrations of ethanol with
0.3 M ammonium acetate (NH4OAc) followed by 100%
ethanol. Slides were air-dried and placed in X-ray film
cassettes with BMR-2 film (Kodak, UK) for 72 h and
developed on an OPTIMAX X-ray film processor. For
assessment of gene expression in the autoradiograph
films were subjected to densitometry analysis using
ImageJ. Integrated mean density values were calculated
for each section containing complete ARC.
For Pomc and Npy analysis, n = 4 for both WT and
PWS-IC groups. For AgRp and Bdnf analysis n = 3 for
both groups.
WAY-161503 induced cessation of feeding
WAY-161503 hydrochloride (Tocris, Missouri USA) was
dissolved in distilled water. The study was conducted as
a within-subjects Latin square design, with at least 72 h
between treatments. Food was removed at the onset of
the dark cycle and the animals fasted for 16 h (water
was available ad libitum). The following morning male
and female WT (n = 14) and PWS-IC (n = 12) animals
were treated with a single injection (sub cutaneous, s.c.)
of either vehicle or WAY-161503 (3 and 10 mg/kg) and
15 min later presented with a known weight of mash
and allowed to freely consume for 60 min. At the end of
the test the remaining food (plus any spillage) was re-
weighed. Food consumption was normalised to body
weight0.75 (BW0.75).
WAY-161503 induced cFOS immunoreactivity (cFOS-IR)
Animals were treated (s.c.) with either 3 mg/kg WAY-
161503 or vehicle and brains collected 2 h later after
transcardial perfusion with 10% formalin. Brains were
cryoprotected in 20% sucrose and sectioned at 25 μm on
a freezing microtome. Free-floating sections were treated
as previously described [4, 7]. Briefly, sections were incu-
bated overnight at room temperature in blocking solu-
tion containing rabbit anti-cFOS antibody (Calbiochem;
1:8000), washed, and transferred to blocking solution
containing biotinylated donkey anti-rabbit secondary
antibody. After rinsing, staining was visualised using fol-
lowing 3,3′-Diaminobenzidine (DAB). For quantification
of cFOS-IR, sections containing ARC were assigned a
bregma level and the boundaries of the ARC delineated
based on neuro-architecture and the Mouse Brain
Atlas [34]. ARC cFOS-IR cells falling within the de-
fined regions were counted unilaterally and a bilateral
average for the nucleus calculated. For all groups
(WT saline, PWS-IC saline, WT WAY-162503, PWS-
IC WAY-162503) n = 4.
Dual Immunofluorescence Histochemistry (IHC)
For co-localisation of cFOS-IR and POMC-IR, sections
were first treated as detailed above for cFOS-IR and then
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processed for POMC immunofluorescence (rabbit anti-
POMC – Immunostar, 1:1000; anti-rabbit Alexa Fluor-568
– Molecular Probes, 1:1000). For cFOS/POMC colocalisa-
tion sections were imaged on a Zeiss Axioskop 2 micro-
scope and a Zeiss AxioCam HRc digital camera.
Chromogenic cFOS signals were photographed in bright-
field and fluorescent POMC signal under appropriate ex-
citation wavelength and the images merged in Photoshop
CS3 (Adobe Inc).
Statistics
All data were analysed using SPSS 20 (SPSS, USA). Data
were analysed by Student’s t-test (two-way, unless other-
wise indicated) or mixed ANOVA, with between subjects
factor of GENOTYPE (PWS-IC vs. WT), and within
subject factor DOSE (vehicle, 3 mg/kg and 10 mg/kg
WAY-161503). All significance tests were performed at
alpha level of 0.05 and where significant interactions
were identified in the main ANOVA, post-hoc tests using
appropriate pair-wise comparisons were performed. For
repeated measures analyses, Mauchly’s test of sphericity
of the covariance matrix was applied.
Conclusion
Alternate splicing of the serotonin 2C receptor (5-HT2CR)
is negatively regulated by the Snord115, loss of which is
seen in most patients with Prader-Willi syndrome (PWS).
Given the role of serotonin in the regulation of ingestive
behaviour we investigated the pathophysiological implica-
tions of Snord115 deficiency showing that increased levels
of a truncated isoform of 5-HT2CR in the hypothalamus
leads to abnormal 5-HT2CR-mediated appetite in a mouse
model for PWS. We conclude that loss of Snord115 ex-
pression is physiologically relevant to 5-HT2CR mediated
appetite which in turn contributes to general hyperphagia
in most cases of PWS. These findings also are important
for individuals with PWS who may seek to control appe-
tite with the new obesity treatment lorcaserin.
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